MMMichael J. McCarthy

Michael J. McCarthy

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Michael J. McCarthy has a total of 758 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Using multi-trait polygenic scores to predict lithium responsiveness in patients with bipolar disorder

    by Nigussie T. Sharew, Scott R. Clark, Simon Hartmann, Sergi Papiol, Urs Heilbronner, Franziska Degenhardt, Janice M. Fullerton, Liping Hou, Tatyana Shekhtman, Mazda Adli, et al.

    Background: The predictive power of polygenic scores (PGSs) for lithium treatment response in bipolar disorder remains limited. Aims: To enhance the prediction of lithium responsiveness by developing a multi-trait PGS (mt-PGS) combining genetic information from multiple phenotypes implicated in lithium response and/or bipolar disorder aetiology. Method: We analysed data collected from bipolar disorder patients who had received lithium treatment for at least 6 months and participated in the International Consortium on Lithium Genetics study ( N = 2367). The Alda scale was used to assess lithium responsiveness, and treatment outcome was defined as continuous total Alda score (0–10) and categorical outcome (favourable ≥7 versus unfavourable response). PGSs were calculated for 60 phenotypes grouped into 5 clinical–biological clusters: psychiatric and behavioural (#23 phenotypes), cardiometabolic (#17), autoimmune/inflammatory (#5), neurocognitive (#8) and renal function (#7). We applied cross-validated machine learning regression approaches in both outcomes within each cluster, with the selected features from each cluster subsequently combined to construct the final mt-PGS models. Model performance was assessed using explained variance ( R 2 ) for the continuous outcome, and both McFadden’s pseudo- R 2 and standard classification model parameters for the categorical outcome. Results: mt-PGS explained between 5.70% (continuous outcome) and 9.11% (categorical outcome) of the interindividual variability in lithium responsiveness. Classification accuracy (area under the curve) for the categorical outcome was 68.24% (95% CI: 64.98–71.66), with a Brier score of 0.257. Of the 5 clusters, the PGSs for psychiatric and behavioural phenotypes were most strongly associated with lithium responsiveness, accounting for 3.67–6.52% of its variability. Conclusions: By integrating PGSs for multiple relevant phenotypes, predictive accuracy for lithium response improved substantially compared with single-trait methods. Future research incorporating larger, more diverse populations and combining genetic scores with clinical data holds promise for further enhancing prediction and advancing clinical implementation.

  • Clinical and Biological Characterization of Bipolar Disorder Patients With Chronic Insomnia Reveals Cortisol Reductions, Elevated TNF ‐α, and Increased Genetic Risk for Accelerated Aging

    by Kayla E. Rohr, Charles B. Schaffer, Linda C. Schaffer, Thomas E. Nordahl, Pei‐An Shih, John R. Kelsoe, Michael J. McCarthy

    Background: Among patients with bipolar disorder, chronic insomnia is a common comorbidity that adversely affects mood instability, quality of life, disability, accelerated aging, and increased suicide risk. Methods: This matched case–control study characterized the clinical features of insomnia in a bipolar disorder clinic population and identified biological and genetic correlates affecting diurnal patterns of cortisol, inflammation, and aging. Cross‐sectional data were collected from 22 patients with bipolar disorder and chronic insomnia (BD + INS), and 22 age‐ and sex‐matched bipolar disorder patients without insomnia (BD‐INS). Results: BD + INS patients reported sleep problems independent of current mood state with a mean insomnia duration of 22.5 years. Compared to BD‐INS participants, BD + INS patients reported more disturbed sleep, more use of daytime anxiolytics, and reduced use of antidepressants, but reported no differences in overall functioning, quality of life, or severity of mood episodes. Compared to matched participants, BD + INS patients also had reduced waking cortisol, increased levels of the inflammatory cytokine tumor necrosis factor α (TNF‐α), and were more likely to be homozygous for a genetic variant in TERT previously linked with short telomere length and premature aging. Conclusions: These findings suggest that chronic insomnia in BD can persistently alter sleep independent of mood symptoms and may be associated with distinct biological features, including cortisol and inflammatory systems.

  • Open Access

    Modulation of neuronal excitability and plasticity by BHLHE41 conveys lithium non-responsiveness

    by Marius Stephan, Sergi Papiol, Mingyue Zhang, Jie Song, Samuel M. Frommeyer, Helen Haupt, Niels Jensen, Nirmal Kannaiyan, Rajinder Gupta, Philipp Schuler, et al.

    Many bipolar disorder (BD) patients are non-responsive to lithium. The mechanisms underlying lithium (non-)responsiveness are largely unknown. By using gene-set enrichment analysis methods, we found that core clock gene-sets are significantly associated with lithium response. Among the top hits was BHLHE41 , a modulator of the molecular clock and homeostatic sleep. Since BHLHE41 and its paralog BHLHE40 are functionally redundant, we assessed chronic lithium response in double-knockout mutant mice (DKO). We demonstrated that DKOs are non-responsive to lithium’s effect in various behavioral tasks. Cellular assays and patch clamp recordings revealed lowered excitability and reduced lithium-response in prefrontal cortical layer 2/3 DKO neurons and on hippocampal long-term potentiation. Single-cell RNA sequencing identified that lithium deregulated mitochondrial respiration, cation channel and postsynapse associated gene-sets specifically in upper layer excitatory neurons. Our findings show that lithium acts in a highly cell-specific way on neuronal metabolism and excitability and modulates synaptic plasticity depending on BHLHE40/41.

  • Mood and Psychosis Risk–Associated Genes Regulate Neuronal Circadian Rhythms Across the Transcriptome

    by Xiangning Xue, Zoe Adelsheim, Michael T. Gorczyca, Heather Wei, Michael J. Leone, Ryan W. Logan, Michael J. McCarthy

  • Proposal for Circadian Rhythms and Their Behavioral Outputs as Biomarkers in DSM-6 : Response to Cuthbert et al.

    by Jacob J. Crouse, Joanne S. Carpenter, Angus C. Burns, Tone E. G. Henriksen, Michael J. McCarthy, Kathleen R. Merikangas, Nicholas Meyer, Jan Scott, Mirim Shin, Daniel J. Smith, et al.


  • Open Access

    Depression Risk in Type 1 Versus Type 2 Diabetes: Cross‐Sectional Analysis of Body Mass Index ( BMI ) in a Nationally Diverse Cohort

    by Natalia Cruz‐Vespa, Michael L. Thomas, Michael J. McCarthy, Alejandro D. Meruelo

    Introduction: Major depressive disorder (MDD) commonly co‐occurs with diabetes, but comparative risk across type 1 diabetes (DM1), type 2 diabetes (DM2) and non‐diabetic groups—and the role of body mass index (BMI)—remains uncertain. Methods: Using All of Us Research Program data, adults were classified as DM1, DM2 or non‐diabetic. Multivariable logistic regression estimated odds of MDD adjusting for age, sex at birth, race and ethnicity; BMI was added in secondary models. Effect modification by sex and race was tested. Structural equation modelling (SEM) assessed whether BMI statistically explained group differences. Results: In models excluding BMI, both DM1 and non‐diabetic participants had higher odds of MDD than DM2 (DM1 vs. DM2: OR = 1.53, 95% CI 1.17–1.99; non‐diabetic vs. DM2: OR = 1.20, 95% CI 1.16–1.25). Interactions by sex and race were significant; contrasts were stronger among females and heterogeneous across race strata. Adding BMI yielded directionally consistent group estimates and confirmed an independent association of higher BMI with higher MDD odds. SEM indicated statistical suppression for the non‐diabetic vs. DM2 contrast: non‐diabetic status related to lower BMI, while higher BMI related to higher MDD, producing a small indirect effect (~8%). The indirect path for DM1 vs. DM2 was non‐significant. Conclusions: Compared with DM2, both DM1 and non‐diabetic groups show higher adjusted odds of MDD. BMI is independently related to MDD but only modestly—and partly suppressively—accounts for the non‐diabetic vs. DM2 contrast. Findings support subgroup‐aware screening and the need for longitudinal data to clarify mechanisms.

  • Open Access

    Body mass index mediates the relationship between depression and triglyceride levels: Evidence from a large national cohort

    by Bhaavyaa B. Shah, Michael L. Thomas, Michael J. McCarthy, Alejandro D. Meruelo


  • Open Access

    Sleep and circadian disorders as risk factors for autoimmune disease: A population-based study

    by Amber R. Li, Bhaavyaa Shah, Michael L. Thomas, Michael J. McCarthy, Alejandro D. Meruelo


  • Circadian clock genes and cell survival in bipolar disorder: Insights into lithium responsiveness and molecular mechanisms in patient‐derived neural progenitor cells and mouse neurons

    by Himanshu K. Mishra, Heather Wei, Melissa LeRoux, Daniel Ko, Kayla Rohr, Caroline M. Nievergelt, Adam X. Maihofer, Paul D. Shilling, Martin Alda, Wade H. Berrettini, et al.

    Bipolar disorder (BD) is characterized by disrupted circadian rhythms and neuronal loss. Lithium amplifies circadian rhythms and is neuroprotective, indicating mechanistic overlap across cellular systems. We examined the role of neuroprotection in determining lithium response and how circadian clock genes regulate apoptosis. In stem‐cell‐derived neuronal progenitor cells (NPCs) from BD patients, and in immortalized mouse hippocampal neurons, lithium was neuroprotective against staurosporine (STS)‐induced apoptosis. However, neuroprotection did not distinguish lithium‐responders (Li‐Rs) from nonresponders (Li‐NRs). Disruption of selected clock genes—period circadian regulator 1 ( PER1 ), basic helix–loop–helix ARNT like 1 ( ARNTL , also known as BMAL1 ), and nuclear receptor subfamily 1 group D member 1 ( NR1D1 ; also known as REV‐ERBα )—with small interfering RNA (siRNA) had distinct effects on apoptosis in mouse neurons and human NPCs. In BD patient NPCs, reduced expression of PER1 and BMAL1 increased apoptosis more in Li‐NR NPCs vs. Li‐R NPCs. Reduced expression of REV‐ERBα caused more extensive apoptosis in BD vs. control NPCs, but did not distinguish Li‐Rs vs. Li‐NRs. The REV‐ERB agonist GSK4112 was neuroprotective in mouse neurons and control NPCs, but did not reduce apoptosis in BD NPCs. Simultaneous treatment of NPCs with STS and GSK4112 revealed BD‐ and Li‐R‐associated differences in apoptosis‐related gene expression. In summary, the pharmacological effects of lithium in promoting neuroprotection are not sufficient to distinguish between Li‐Rs and Li‐NRs. However, genetic and pharmacological manipulations of the circadian clock reveal distinct roles in apoptosis in BD patient NPCs, some of which do distinguish Li‐Rs and Li‐NRs. We conclude that genetic disruption of cellular circadian clocks may predispose neurons to apoptosis preferentially in BD and/or Li‐NR. These findings imply that differences in BD between Li‐Rs/Li‐NRs primarily arise from defining biological characteristics of patient subgroups, not from distinct pharmacodynamic factors following lithium treatment.